Roman Fabbricatore

The use of an ultrasensitive assay was able to detect HPV-16-positive SiHa cells at greater than 500 cells/mL for cervical cancer.

The results of the trial showed that at least 75% of patients with NSCLC harboring driver gene alterations may benefit from this treatment.

Results from the phase 2b TACTI-003 trial show that eftilagimod alfa plus pembrolizumab achieved high objective response and disease control rates.

Results from a retrospective cohort study display evidence of potential benefit from GLP-1RAs for the reduction of 13 obesity-associated cancers for those with type 2 diabetes.

Findings from the phase 3 FLAURA2 trial support the European approval of osimertinib/chemotherapy in EGFR-mutated non–small cell lung cancer.

Fertility and sexual health services appear to be offered to cancer survivors less often than other services at CoC-accredited practices.

A statistically significant and clinically meaningful improvement in progression-free survival in the phase 3 trial DUO-E support the recommendation.

Study results suggest follow-up with hypercholesterolemia control and audiological assessments for cisplatin-treated patients with cancer.

Data also show statistically meaningful improvements in endocrine symptoms and breast cancer–specific quality of life with acupuncture.

The announcement follows results from the ENVASARC trial, where the primary endpoint needed to support a biologics license application was not met.

Tissue biopsy was recommended among Black patients at risk of endometrial cancer over the common ultrasonography triage strategy.

In addition to tissue biopsy, a liquid biopsy test can be used to better identify patients who may benefit from niraparib and abiraterone acetate.

The new recommendation update modifies a 2020 ASCO guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer.

The first-in-class tetravalent bispecific antibody may show binding affinity to PD1 and VEGF based on in vitro studies.

In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.

Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

The approval for osimertinib/chemotherapy by the Japanese Pharmaceuticals and Medical Device Agency was based on results from the phase 3 FLAURA2 trial.

Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.

Vikek S. Kavadi, MD, MBA, FASTRO, succeeds Laura Thevenot, who plans to retire at the end of 2024 after leading the organization since 2002.

Two deaths due to presumed sepsis in patients treated in the DENALI trial led to the clinical holds on the advanced solid tumor treatment.

Longer survival rates were experienced by patients receiving chemotherapy both before and after surgery vs only after surgery.

Approved for use in newly diagnosed and previously treated myelofibrosis, momelotinib may addresses key manifestations of the disease.

As the practice of radiation therapy evolves in HPV-associated OPSCC, updated evidence-based ASTRO guidelines may help inform clinical practices.

Golidocitinib monotherapy had a superior clinical benefit in patients with relapsed/refractory peripheral T-cell lymphoma vs existing treatments.

Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.

A minimally invasive cryoablation technology system designed to treat patients with kidney tumors and elicit an 89.65% recurrence-free rate.

Findings from a retrospective study showed that outpatient robotic hepatectomies resulted in no mortalities across 307 procedures.

Four trajectories of change were identified in FACT-PWB score, with large patient groups experiencing little to no change or slight declines in PWB.

A trial for BNT326/YL202 in EGFR-mutated NSCLC or HR-positive HER2-negative breast cancer has paused enrollment due to a large illness or injury risk.

Data from the phase 3 PALOMA study showed subcutaneous amivantamab had comparable ORR to intravenous administration for patients with EGFR-mutated NSCLC.